Our Research Team
The diabetes research unit is composed of an interdisciplinary team engaged in basic, translational and clinical diabetes research. The department is engaged in a number of research studies, many sponsored by the pharmaceutical industry, which aim to help develop more effective treatment and management options for patients with diabetes. Research interests of our team include: diabetes types 1 and 2, atypical diabetes, MODY, inpatient diabetes management, and diabetes pathophysiology and the role of T cells. For more information, visit Boston University School of Medicine’s Diabetes Research page.
Basic Science Investigators
Research Support Staff
Ashley McCarthy - Clinical Research Manager
Christina Nowak - Senior Research Assistant
Mary-Catherine Stockman, MPH, RD, LDN - Research Dietitian and Coordinator
Please click on the study title for more information.
This clinical trial is comparing the effect of insulin degludec and insulin glargine. Participants will first go through a 4-week screening and run-in period. If eligible to continue in the study, participants will be treated with insulin degludec (100 U/mL) and insulin glargine (100 U/mL) during two different periods each of 18 weeks duration. Both medicines are approved for use in humans and available on the market. In order to evaluate changes in blood sugar level over time while being treated with the two different insulins, participants will be asked to wear a small blood sugar sensor on the back of their upper arm 3 times during the study. To see if you may be eligible for the study, please take this brief questionnaire.
The INSTRIDE 4 Study is looking at the ways the investigational insulin works to control blood sugar levels in patients with Type 1 Diabetes and to check how safe they are. All participants in this study receive the potentially long-acting investigational medication, in addition to an FDA-approved, rapid-acting insulin at mealtimes. Approximately 200 people are participating in this study internationally. The study is about 26 weeks (6 months) long.
We are currently creating a registry of interested individuals who would like to participate in research at Boston Medical Center or Boston University School of Medicine. The option to join the registry is voluntary. Joining will not affect the care you receive at Boston Medical Center. For more information, please read the ENDO Registry Consent Form. To enroll in the registry, please go to the secure enrollment portal. If you have questions prior to enrolling, please email Mary-Catherine Stockman, MPH, RD, LDN or call 617.638.5921.
Estamos creando un registro de individuos interesados en participar en estudios de investigación en Boston Medical Center o Boston University School of Medicine. Participar en el registro es voluntario. Participar no afectará la atención recibida en Boston Medical Center. Para más información, por favor leer el formulario de consentimiento. Para inscribirse en el registro, por favor ingresar a https://is.gd/ENDOregistry_Spanish.
Boston Medical Center was one of hundreds of sites to conduct the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The 52-week, open label trial investigated the efficacy and safety of 14 mg oral semaglutide compared with 25 mg empagliflozin in 816 people with type 2 diabetes, inadequately controlled on metformin. The confirmatory endpoints were defined after 26 weeks of treatment. Read their full results announcement here.
Full title: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients with Type 2 Diabetes. This study compared linagliptin (a once-daily diabetes pill) plus as-needed rapid insulin shots vs. long acting insulin glargine plus scheduled rapid insulin shots for the treatment of diabetes patients after they have surgery. Approximately 280 participants from 4 United States medical centers participated.
Full title: The safety and efficacy of Linagliptin (Tradjenta®) therapy for an A1c directed post-discharge management algorithm of general surgery patients with type 2 diabetes: Only thos individuals who completed the Linagliptin Inpatient Trial were invited to participate in this extended study. This study compared the effect of Linagliptin (diabetes pill) with insulin shots for the treatment of diabetes after participants left the hospital.
Technology usage among patients in the Center for Endocrinology, Diabetes, Nutrition and Weight Management
The purpose of this survey was to characterize the patient population of the BMC Endocrinology, Diabetes, Nutrition and Weight Management Clinic. We sought to dispel myths about technology access and usage among our patients. The survey was adapted from Pew Research Center’s technology questionnaire and their data. The survey contained questions about internet usage, device ownership, preferred communication methods, use of technology for health, social media usage, and optional demographic information.
Patients and visitors: If you are interested in hearing about studies that you may be able to participate in, please consider enrolling in the ENDO Registry. Alternatively, you may email Mary-Catherine Stockman or call 617.638.5921.
Are you interested in learning more about clinical research? Please visit our Clinical Research Basics page.